December 1, 2010Current Pharmaceutical Design
Targeting the Platelet Integrin GPIIb/IIIa
Key result
GPIIb/IIIa inhibitors are effective anti-platelet agents in cardiovascular medicine, though oral antagonists have failed and there remains a need for orally active drugs with lower bleeding risk.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Underscores unmet need for safer oral GPIIb/IIIa inhibitors; leaves open optimal designs for future agents.
Structured PICO
I
Intervention
GPIIb/IIIa inhibitors (abciximab, eptifibatide, and tirofiban)
This review summarizes the current knowledge on GPIIb/IIIa inhibitors, their clinical utility in cardiovascular medicine, and the ongoing need for safer, orally available alternatives.
Limitations
- Oral GPIIb/IIIa antagonists have not been successful
- Unmet need for effective anti-GPIIb/IIIa drugs that cause less bleeding problems and that can be orally applied
Cite This Study
Hagemeyer et al. (2010) conducted a review in Cardiovascular disease (unstable angina, myocardial infarction, high risk percutaneous coronary interventions). GPIIb/IIIa inhibitors was evaluated. GPIIb/IIIa inhibitors are effective anti-platelet agents in cardiovascular medicine, though oral antagonists have failed and there remains a need for orally active drugs with lower bleeding risk.